Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Todo

Showing results (11-20 of 96) with videos related to

Pageof 10
Sort By:
Japanese Journal of Clinical Oncology|November 22, 2018
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectivesSatoru Taguchi, Hiroshi Fukuhara, Tomoki Todo
Cancer Science|August 4, 2016
Oncolytic virus therapy: A new era of cancer treatment at dawnHiroshi Fukuhara, Yasushi Ino, Tomoki Todo
Cancer Science|May 26, 2021
Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumorsHiroshi Fukuhara, Yuta Takeshima, Tomoki Todo
International Journal of Urology : Official Journal of the Japanese Urological Association|October 17, 2009
Oncolytic virus therapy for prostate cancerHiroshi Fukuhara, Yukio Homma, Tomoki Todo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacyYasushi Ino, Yoshinaga Saeki, Hiroshi Fukuhara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 23, 2017
Current status of clinical trials assessing oncolytic virus therapy for urological cancersSatoru Taguchi, Hiroshi Fukuhara, Yukio Homma, et al.
Molecular Therapy Oncolytics|September 30, 2020
Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency AblationTomoharu Yamada, Ryosuke Tateishi, Miwako Iwai, et al.
Nature Communications|July 21, 2022
A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastomaTomoki Todo, Yasushi Ino, Hiroshi Ohtsu, et al.
Molecular Cancer Therapeutics|May 5, 2026
Oncolytic Herpes Virus G47∆ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune ResponsesTakafumi Nagatomo, Miwako Iwai, Minoru Tanaka, et al.
Cancer Science|June 20, 2025
Epithelial-Mesenchymal Transition and Genetically Driven Early Tumor Seedings in Extraneural Metastasis of GlioblastomaSeisaku Kanayama, Kentaro Watanabe, Minoru Tanaka, et al.
Pageof 10

Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
Japanese Journal of Clinical Oncology|November 22, 2018
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectivesSatoru Taguchi, Hiroshi Fukuhara, Tomoki Todo
Cancer Science|August 4, 2016
Oncolytic virus therapy: A new era of cancer treatment at dawnHiroshi Fukuhara, Yasushi Ino, Tomoki Todo
Cancer Science|May 26, 2021
Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumorsHiroshi Fukuhara, Yuta Takeshima, Tomoki Todo
International Journal of Urology : Official Journal of the Japanese Urological Association|October 17, 2009
Oncolytic virus therapy for prostate cancerHiroshi Fukuhara, Yukio Homma, Tomoki Todo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacyYasushi Ino, Yoshinaga Saeki, Hiroshi Fukuhara, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 23, 2017
Current status of clinical trials assessing oncolytic virus therapy for urological cancersSatoru Taguchi, Hiroshi Fukuhara, Yukio Homma, et al.
Molecular Therapy Oncolytics|September 30, 2020
Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency AblationTomoharu Yamada, Ryosuke Tateishi, Miwako Iwai, et al.
Nature Communications|July 21, 2022
A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastomaTomoki Todo, Yasushi Ino, Hiroshi Ohtsu, et al.
Molecular Cancer Therapeutics|May 5, 2026
Oncolytic Herpes Virus G47∆ Potentiates ADCC-Inducing Molecular Targeted Therapy via Coordinated Activation of Innate and Adaptive Immune ResponsesTakafumi Nagatomo, Miwako Iwai, Minoru Tanaka, et al.
Cancer Science|June 20, 2025
Epithelial-Mesenchymal Transition and Genetically Driven Early Tumor Seedings in Extraneural Metastasis of GlioblastomaSeisaku Kanayama, Kentaro Watanabe, Minoru Tanaka, et al.
Pageof 10